Navigation Links
QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System
Date:7/28/2009

VANCOUVER, July 28 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced encouraging interim data from an ongoing Phase II clinical trial and a device study for the punctal plug delivery system. These studies are part of a development program that is being conducted by QLT's wholly-owned subsidiary, QLT Plug Delivery, Inc.

Preliminary interim results from the ongoing Phase II clinical trial of the 44-(micro)g Latanoprost Punctal Plug Delivery System (L-PPDS) show that the mean change in intraocular pressure (IOP) from baseline was -3.5 mmHg at the Week 4 visit with 36% of patients having an IOP decrease from baseline (greater than or equal to)5 mmHg. The 44-(micro)g L-PPDS employs an early, proprietary punctal plug prototype, and based on a review of the preliminary data, it was well tolerated.

These results from the ongoing Phase II clinical trial evaluating the safety, efficacy, and dosing of the L-PPDS for the treatment of open angle glaucoma (OAG) and ocular hypertension (OH) are based on IOP data from 47 patients treated with the 44-(micro)g L-PPDS for four weeks. The objective of this trial is to evaluate two doses of latanoprost (44 (micro)g and 81 (micro)g) to contribute data to identify the most promising formulations for a Phase II dose-ranging and a subsequent Phase III registration trial. Subjects are currently enrolling to receive the 81-(micro)g dose formulation, and the Company plans to initiate clinical evaluations of two to three additional higher dose formulations later this year. The goal of these studies is to identify novel formulations that achieve a (greater than or equal to)5 mmHg drop in mean IOP.

The 44-(micro)g L-PPDS is roughly equivalent to 29 latanoprost eye drops, or about one-third the amount of drug in eye drops given continuously over three months. The 81-(micro)
'/>"/>

SOURCE QLT Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. QLT Announces Second Quarter Results for 2009
2. MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Advantage
3. Grupo Casa Saba Announces Quarterly Earnings Report 2Q09
4. Image Sensors 2009 Announces Final Program and New Interactive Brochure
5. ULURU Inc. Announces Status of York Note Receivable
6. Danaher Corporation Announces Retirement of Executive Vice President Philip W. Knisely
7. Paradigm Spine Closes $21.5 Million Financing and Announces Promotion of Matt Stuttle to Position of Vice President, US Sales
8. Electronic Healthcare Network Announces Multi-State Expansion, Beginning in Buffalo, NY
9. Association of Gaming Equipment Manufacturers (AGEM) Announces $100,000 in Contributions to Organizations Working to Assist Problem Gamblers
10. American DG Energy Announces $3.5 Million Private Placement
11. Brookdale Announces Second Quarter 2009 Release and Earnings Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... ... Extension Vending Machine,” is still strongly maintaining her firm’s success in the hair ... tools. In her upcoming city-to-city tour, Ellis will be providing “Look and learn” ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... has announced that Edge Information Management has been granted continued accreditation ... Credentialing Council (BSCC). , “Achieving and maintaining this accreditation takes the ...
(Date:9/1/2015)... ... , ... With former IBMers among its founding members, Inmar has known the ... 35 years ago. A pilot program begun by the company in 2014 has proved ... intent on pursuing careers in these fields. The program is now open to area ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Royal River ... new study that followed men and women for 19 years and found that, among ... did not take multivitamins. , The report is part of the September 2015 issue ...
(Date:9/1/2015)... ... September 01, 2015 , ... The FSH Society , ... facioscapulohumeral muscular dystrophy (FSHD), will be the beneficiary of a collection of fundraising events ... to raise awareness of the FSH Society and further FSHD research. , ...
Breaking Medicine News(10 mins):Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3
... now infarct size has only been measured as part of ... being that the reference method of gadolinium based contrast agents ... to perform, and can only be undertaken by imaging specialists," ... Padua, Italy. "The advantages of STE over MRI is that ...
... HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay News) -- Working ... may also increase your risk of developing type 2 diabetes, new ... found that those who worked rotating night shifts were more likely ... the longer that they worked a rotating shift schedule, the greater ...
... TX - Accelerated partial breast irradiation (APBI) brachytherapy, ... popular as a treatment choice for women with ... of later mastectomy, increased radiation-related toxicities and post-operative ... according to researchers from The University of Texas ...
... Denise Mann HealthDay Reporter , TUESDAY, Dec. 6 ... for preterm birth as early as 23 weeks during their ... reduce the baby,s risk of serious developmental issues, including brain ... the Dec. 7 issue of the Journal of the ...
... , TUESDAY, Dec. 6 (HealthDay News) -- U.S. ... remove controversial, unapproved and illegally labeled HCG weight loss products ... a hormone made by the human placenta and found in ... in conjunction with an extremely low-calorie diet -- as low ...
... Reinberg HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay ... with hormone therapy do not appear to be at increased ... new review of evidence. Hormone therapy called "androgen ... previous studies found that the therapy might increase the risk ...
Cached Medicine News:Health News:Echocardiography offers the future for infarct size quantification 2Health News:Echocardiography offers the future for infarct size quantification 3Health News:Echocardiography offers the future for infarct size quantification 4Health News:Rotating Shift Work May Boost Women's Diabetes Risk 2Health News:Rotating Shift Work May Boost Women's Diabetes Risk 3Health News:Study finds side effects, complications, mastectomy more likely after partial breast irradiation 2Health News:Study finds side effects, complications, mastectomy more likely after partial breast irradiation 3Health News:Steroids May Boost Survival for Very Preemie Babies 2Health News:FDA Targets Homeopathic Weight Loss Products 2Health News:FDA Targets Homeopathic Weight Loss Products 3Health News:FDA Targets Homeopathic Weight Loss Products 4Health News:Hormone Drugs Might Not Raise Heart-Related Deaths in Prostate Patients 2Health News:Hormone Drugs Might Not Raise Heart-Related Deaths in Prostate Patients 3
(Date:9/1/2015)... Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) today ... evaluating effect of RomosozUmab Compared with Teriparatide in ... fracture pReviously treated with bisphosphonatE therapy). The study ... significant difference in favor of romosozumab in the ...
(Date:9/1/2015)... Sept. 1, 2015 Emerus Holdings, a ... emergent, inpatient and diagnostic care in partnership with ... a definitive agreement to receive a strategic investment ... a leading health care investment firm. ... patient-centric acute episodic and ambulatory clinical services to ...
(Date:9/1/2015)... IRVINE, Calif. , Sept. 1, 2015  Edwards ... in the science of heart valves and hemodynamic monitoring, ... Fargo Healthcare Conference at the Hyatt Regency Boston in ... 9, 2015. Michael A. Mussallem , ... keynote lunch speaker followed by a company discussion with ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: ... emerging leader in the development, assembly, marketing and sale ... that the Company,s growing business earned a BBB+ Credit Rating ... "Zhongguancun Association") and was approved as a member of ...
... SHANGHAI, Feb. 28, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... China-based pharmaceutical and biotechnology research and development outsourcing company, ... results for the fourth quarter and full year ended ... host a conference call to discuss the results at ...
Cached Medicine Technology:Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 2Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 3ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012 2
... The SeedVac™ is a vacuum driven device designed to ... tube tip. Seeds are drawn into the clear tube ... the hand piece to create the vacuum. The prescribed ... the clear tube tip before being placed into the ...
MT-BT-5001-25 prostate seeding needle (set of 25 unloaded needles).,MT-BT-5001-P prostate seeding needle, pre-plugged and pre-sterilized, unloaded or for use with MEDTECs ASAP™ pre-load seeding...
... a myoma was performed with a cutting ... vaporization of myomas with the VaporTrode Vaporization ... tissue chips that obscure visibility. No tissue ... This unique design provides areas of high ...
... The 19 Fr. OES 4000 Nephroscope, with ... quality with outstanding durability. The lumbotome, for ... the telescopic bougies, allow safer access. The ... comprehensive range of grasping forceps and lithotripsy ...
Medicine Products: